Narrow search
Showing 1 - 10 of 35,791
Cover Image
Modelling the Budget Impact of Darunavir in the Treatment of Highly Treatment-Experienced, HIV-Infected Adults in France
Colin, Xavier; Lafuma, Antoine; Costagliola, Dominique; … - In: PharmacoEconomics 28 (2010) S1, pp. 183-197
Background: A key element for payers in the assessment of the economic profile of a medication is its anticipated impact on the evolution of healthcare budgets. Objectives: To forecast the impact of the use of darunavir with low-dose ritonavir 600/100 mg twice a day (bid) in highly...
Persistent link: https://www.econbiz.de/10010614360
Cover Image
Cost-Efficacy Analysis of the MONET Trial Using UK Antiretroviral Drug Prices
Gazzard, Brian; Hill, Andrew; Anceau, Anne - In: Applied Health Economics and Health Policy 9 (2011) 4, pp. 217-223
antiretrovirals taken after initial treatment failure. By this analysis, efficacy was 93.5% versus 95.1% in the DRV/r monotherapy and … annual cost of antiretrovirals was £6906 for patients receiving NNRTI-based HAART, and £8348 for patients receiving PI …-based HAART. During the MONET trial, the mean annual per-patient cost of antiretrovirals was £8642 in the triple therapy arm, of …
Persistent link: https://www.econbiz.de/10010614281
Cover Image
Medical Resource Utilization and Cost of HIV-Related Care in the Highly Active Antiretroviral Therapy Era at a University Clinic in Sweden
Ghatnekar, Ola; Hjortsberg, Catharina; Gisslén, Magnus … - In: PharmacoEconomics 28 (2010) S1, pp. 49-57
Introduction: Little is known regarding healthcare costs for HIV/AIDS patients in the era of highly active antiretroviral therapy (HAART) and subgroups of patients according to the severity and progression of HIV infection in Sweden. The objective of this study is therefore to describe the...
Persistent link: https://www.econbiz.de/10011005075
Cover Image
A Multicentre Study of Patient Survival, Disability, Quality of Life and Cost of Care: Among Patients with AIDS in Northern Italy
Tramarin, Andrea; Campostrini, Stefano; Postma, Maarten J. - In: PharmacoEconomics 22 (2004) 1, pp. 43-53
Objective: To describe the epidemiological, clinical and economic changes that occurred in the HIV epidemic in Italy prior to and after the introduction of highly active antiretroviral therapy (HAART). Design: A prospective, observational, multicentre case-control study was conducted comparing...
Persistent link: https://www.econbiz.de/10005243101
Cover Image
The Cost of Managing HIV Infection in Highly Treatment-Experienced, HIV-Infected Adults in France
Colin, Xavier; Lafuma, Antoine; Costagliola, Dominique; … - In: PharmacoEconomics 28 (2010) S1, pp. 59-68
Background: Highly active antiretroviral therapy (HAART) has greatly enhanced HIV management, lowering the risk of clinical disease progression and death by substantially improving HIV-induced immune deficiency. Lower CD4 cell counts have consistently been associated with higher direct costs of...
Persistent link: https://www.econbiz.de/10010614302
Cover Image
US Cost Effectiveness of Darunavir/Ritonavir 600/100 mg bid in Treatment-Experienced, HIV-Infected Adults with Evidence of Protease Inhibitor Resistance Included in the TITAN Trial...
Brogan, Anita; Mauskopf, Josephine; Talbird, Sandra E.; … - In: PharmacoEconomics 28 (2010) S1, pp. 129-146
Introduction: The phase III TITAN trial evaluated the use of darunavir with low-dose ritonavir (DRV/r) 600/100 mg twice daily (bid) compared with lopinavir with low-dose ritonavir (LPV/r) in treatment-experienced, lopinavir-naive patients. This study estimates the cost effectiveness of DRV/r...
Persistent link: https://www.econbiz.de/10010614305
Cover Image
Cost Effectiveness of Darunavir/Ritonavir 600/100 mg bid in Treatment-Experienced, Lopinavir-Naive, Protease Inhibitor-Resistant, HIV-Infected Adults in Belgium, Italy, Sweden and...
Moeremans, Karen; Hemmett, Lindsay; Hjelmgren, Jonas; … - In: PharmacoEconomics 28 (2010) S1, pp. 147-167
Background: Using data from the phase IIb POWER trials, darunavir boosted with low-dose ritonavir (DRV/r; 600/100 mg twice daily; bid)-based highly active antiretroviral therapy (HAART) was shown to be significantly more efficacious and cost effective than other protease inhibitor (PI)-based...
Persistent link: https://www.econbiz.de/10010614331
Cover Image
Predicting Direct Costs of HIV Care During the First Year of Darunavir-Based Highly Active Antiretroviral Therapy Using CD4 Cell Counts: Evidence from POWER
Hill, Andrew M.; Gebo, Kelly; Hemmett, Lindsay; … - In: PharmacoEconomics 28 (2010) S1, pp. 169-181
Background: Given the association between CD4 cell counts and HIV-related morbidity/mortality, new antiretroviral therapies could potentially lower the direct costs of HIV care by raising CD4 cell counts. Objectives: To predict the effects of the ritonavir-boosted, HIV protease inhibitor (PI)...
Persistent link: https://www.econbiz.de/10010614341
Cover Image
A Review of Economic Evaluations of Darunavir Boosted by Low-Dose Ritonavir in Treatment-Experienced Persons Living with HIV Infection
Mauskopf, Josephine; Annemans, Lieven; Hill, Andrew M.; … - In: PharmacoEconomics 28 (2010) S1, pp. 1-16
Darunavir boosted by low-dose ritonavir (DRV/r), at a daily dose of 600/100 mg twice a day (bid), has been shown to be superior to alternative highly active antiretroviral therapy (HAART) regimens for the management of treatment-experienced, HIV-infected adults in the phase IIb POWER trials...
Persistent link: https://www.econbiz.de/10010614342
Cover Image
Clinical Management of Treatment-Experienced, HIV/AIDS Patients in the Combination Antiretroviral Therapy Era
Boyd, Mark A.; Hill, Andrew M. - In: PharmacoEconomics 28 (2010) S1, pp. 17-34
Despite the success of combination antiretroviral therapy (ART) in improving clinical outcomes, treatment failure remains a significant challenge, particularly for highly treatment-experienced patients. This review evaluates current issues in the management of HIV-infected, treatment-experienced...
Persistent link: https://www.econbiz.de/10010614400